Prognostic factor analysis of irreversible electroporation for locally advanced pancreatic cancer A multi -institutional clinical study in Asia

被引:11
|
作者
Yang, Po-Chih [1 ,2 ,3 ]
Huang, Kai-Wen [1 ,4 ,5 ]
Pua, Uei [6 ]
Kim, Man-Deuk [7 ]
Li, Sheng-Ping [8 ]
Li, Xiao-Yong [9 ]
Liang, Po-Chin [10 ]
机构
[1] Natl Taiwan Univ, Coll Med, Grad Inst Clin Med, Taipei, Taiwan
[2] Fu Jen Catholic Univ, Fu Jen Catholic Univ Hosp, Dept Surg, New Taipei, Taiwan
[3] Fu Jen Catholic Univ, Sch Med, New Taipei, Taiwan
[4] Natl Taiwan Univ Hosp, Dept Surg, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[5] Natl Taiwan Univ Hosp, Hepatitis Res Ctr, 7 Chung Shan South Rd, Taipei 10002, Taiwan
[6] Tan Tock Seng Hosp, Dept Diagnost Radiol, Singapore, Singapore
[7] Yonsei Univ, Res Inst Radiol Sci, Coll Med, Seoul, South Korea
[8] Sun Yat Sen Univ, Canc Ctr, Dept Hepatobiliary Oncol, Guangzhou, Peoples R China
[9] Zhengzhou Univ, Dept Gen Surg, Affiliated Hosp 5, Zhengzhou 450052, Henan, Peoples R China
[10] Natl Taiwan Univ Hosp, Dept Med Imaging, Taipei, Taiwan
来源
EJSO | 2020年 / 46卷 / 05期
关键词
IR; LAP; Prognostic factor; Irreversible electroporation; Locally advanced pancreatic cancer tumor ablation; CHEMOTHERAPY; ADENOCARCINOMA; GEMCITABINE; ABLATION; EXPERIENCE; FOLFIRINOX; SURGERY; SAFETY;
D O I
10.1016/j.ejso.2019.12.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction: Irreversible electroporation (IRE) is a modality that utilizes high electric voltage to cause cell apoptosis. IRE has been used to treat locally advanced pancreatic cancer (LAPC). However, studies of IRE via surgical approaches for LAPC are limited. This study aims to analyse the outcomes and related prognostic factors of IRE for Asian patients with LAPC. Materials and methods: From 2012 to 2017, this prospective trial for using IRE through surgical approaches for LAPC was conducted in 11 medical centres in Asia. All related and treatment outcomes were analysed from a prospective database. Results: Seventy-four patients were enrolled. Thirty complications occurred in thirteen (17.6%) patients without mortality. The electrode placement direction (anteroposterior vs. craniocaudal, HR = 14.2, p < 0.01) and gastrointestinal invasion (HR = 15.7, p < 0.01) were significant factors for complications. The progression-free survival (PFS) rate in one year, three years, and five years were 69.1%, 48.7%, and 28.8%, and the overall survival (OS) rate in one year, three years, and five years were 97.2%, 53%, and 31.2%. In univariate analysis, the chemotherapy regimen, local tumour recurrence, axial tumour length, tumour volume, and serum carbohydrate antigen 19-9 levels were all significantly associated with PFS and OS. In multivariate analysis, the chemotherapy regimen was the only significant factor associated with PFS and OS. TS-1 (Tegafur, gimeracil, and oteracil) group has superior survival outcome than gemcitabine group. Conclusion: This study showed that combined induction chemotherapy and surgical IRE for LAPC is safe. For well-selected patients, IRE can achieve encouraging survival outcomes. (C) 2019 Elsevier Ltd, BASO - The Association for Cancer Surgery, and the European Society of Surgical Oncology. All rights reserved.
引用
收藏
页码:811 / 817
页数:7
相关论文
共 50 条
  • [21] Intraoperative Irreversible Electroporation in Locally Advanced Pancreatic Cancer: A Guide for the Interventional Radiologist
    Frey, Gregory T.
    Padula, Carlos A.
    Stauffer, John A.
    Toskich, Beau B.
    SEMINARS IN INTERVENTIONAL RADIOLOGY, 2019, 36 (05) : 386 - 391
  • [22] Irreversible electroporation for locally advanced pancreatic cancer: A single-center experience
    Tsuchiya, Takayoshi
    Sugimoto, Katsutoshi
    Kamada, Kentaro
    Fujita, Mitsuru
    Yamamoto, Kenjiro
    Matsunami, Yukitoshi
    Nagakawa, Yuichi
    Hosokawa, Yuichi
    Tsuchida, Akihiko
    Moriyasu, Fuminori
    Itoi, Takao
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2017, 32 : 199 - 199
  • [23] Immunomodulatory Effect after Irreversible Electroporation in Patients with Locally Advanced Pancreatic Cancer
    He, Chaobin
    Wang, Jun
    Sun, Shuxin
    Zhang, Yu
    Li, Shengping
    JOURNAL OF ONCOLOGY, 2019, 2019
  • [24] Commentary: The Synergistic Role of Irreversible Electroporation and Chemotherapy for Locally Advanced Pancreatic Cancer
    Granata, Vincenza
    Palaia, Raffaele
    Izzo, Francesco
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [25] Irreversible Electroporation in Locally Advanced Pancreatic Cancer: Potential Improved Overall Survival
    Robert C. G. Martin
    Kelli McFarland
    Susan Ellis
    Vic Velanovich
    Annals of Surgical Oncology, 2013, 20 : 443 - 449
  • [26] Systematic Review of Irreversible Electroporation Role in Management of Locally Advanced Pancreatic Cancer
    Lafranceschina, Stefano
    Brunetti, Oronzo
    Delvecchio, Antonella
    Conticchio, Maria
    Ammendola, Michele
    Curro, Giuseppe
    Piardi, Tullio
    de'Angelis, Nicola
    Silvestris, Nicola
    Memeo, Riccardo
    CANCERS, 2019, 11 (11)
  • [27] CT Findings of Patients Treated with Irreversible Electroporation for Locally Advanced Pancreatic Cancer
    Akinwande, Olaguoke
    Ahmad, Shakeeb S.
    Van Meter, Tracy
    Schulz, Brittany
    Martin, Robert C. G.
    JOURNAL OF ONCOLOGY, 2015, 2015
  • [28] Initial experience of irreversible electroporation for locally advanced pancreatic cancer in a Korean population
    Kwon, Joon Ho
    Chung, Moon Jae
    Park, Jeong Youp
    Lee, Hee Seung
    Hwang, Ho Kyoung
    Kang, Chang Moo
    Lee, Woo Jung
    Park, Mi-Suk
    Kim, Namo
    Bang, Seungmin
    Kim, Man-Deuk
    ACTA RADIOLOGICA, 2021, 62 (02) : 164 - 171
  • [29] Initial experience in irreversible electroporation for the treatment of locally advanced unresectable pancreatic cancer
    Moir, J. A. G.
    Tsirlis, T.
    Littler, P.
    Sumpter, K.
    Jones, M.
    Duncan, H.
    White, S. A.
    French, J. J.
    Manas, D. M.
    BRITISH JOURNAL OF SURGERY, 2016, 103 : 22 - 22
  • [30] Irreversible electroporation of locally advanced pancreatic neck/body adenocarcinoma
    Martin, Robert C. G., II
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2015, 6 (03) : 329 - 335